Fig. 4BHyperoxygenation condition increased the expression of MMP-9 via MeCP2 in HT22 cells. (A~D) Expression levels of
Mecp2,
Pea3,
Mmp-2,
Mmp-9,
tPA, and
uPA genes in HT22 cells treated with siRNA-MeCP2 (A, B) or siRNA-Pea3 (C, D). siCON, siRNA-control; siMeCP2, siRNA-MeCP2; siPea3, siRNA-Pea3. n=6 wells, 4~12 repeats. (E) Expression levels of
Mecp2 and
Pea3 in HT22 cells treated with 20% PFD. Veh, vehicle. n=6 wells, 4~6 repeats. (F) Expression levels of
Mecp2,
Mmp-2,
Mmp-9,
tPA, and
uPA in HT22 cells treated with 20% PFD plus siRNA-MeCP2 or siRNA-control. n=6 wells, 5~7 repeats. (G, H) Photomicrographs showing siRNA-mediated knockdown of MeCP2 in the CA3 of mice. High magnification of boxed areas (G, bottom panels). Transcript levels of
Mecp2 in siRNA-
Mecp2 injection site (G, right). Diagram showing the siRNA-
Mecp2 injection site (G, left). Expression levels (H) of the
Mmp-2,
Mmp-9,
tPA,
uPA, and
Pea3 in siRNA-
Mecp2 injection site. siCON, siRNA-control. Scale bar, 20 μm. n=6 animals/group, 4~8 repeats. (I, J) The proximal promoter regions (I) of the
Mmp-2,
Mmp-9, and
tPA genes and the locations (the colored bar in each promoter) used for qPCR amplification in ChIP assay. ChIP-qPCR data (J) showing MeCP2 binding levels to the promoter of the
Mmp-2,
Mmp-9, and
tPA in the hippocampus of WT-CON, WT-HO
2, Tg-CON, and Tg-HO
2 mice. HO
2 treatment was depicted in
. n=7~11 animals/group, 5~6 repeats. Data are presented as mean±SEM. *
,**difference between indicated groups. *p<0.05; **p<0.01 (Student’s t-test; one-way ANOVA and Newman–Keuls
post hoc test; two-way ANOVA and Bonferroni
post hoc test).
